ThermoGenesis Holdings (THMO) AI Stock Analysis

• Market Cap: $16.00
• Dividend Yield: N/A
• Average Volume (3M): 10.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 41.04
• Revenue Growth: -7.53%
• EPS Growth: 77.39%
• Country: US
• Employees: 25
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): -4.75
• Shares Outstanding: 15,847,517
• 10 Day Avg. Volume: 3,185
• 30 Day Avg. Volume: 10,933
• PEG Ratio: <0.01
• Price to Book (P/B): 0.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.23
• Enterprise Value/Market Cap: 496.95K
• Enterprise Value/Revenue: 0.21
• Enterprise Value/Gross Profit: 3.92
• Enterprise Value/Ebitda: -0.32
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: ―

ThermoGenesis Holdings is facing significant financial and operational challenges, with negative equity, declining revenues, and liquidity issues. The absence of technical analysis data and meaningful valuation metrics further complicates the outlook. The neutral impact of the earnings call does not offset the overall negative financial performance.

ThermoGenesis Holdings Business Overview & Revenue Model

Company Description

ThermoGenesis Holdings (THMO) is a biotechnology company that focuses on the development, commercialization, and licensing of automated technologies for cell processing and cell-based therapies. The company operates within the life sciences sector, providing a range of products and services designed to improve the efficiency and effectiveness of cell therapy manufacturing processes. Core products include automated cell separation systems, cryopreservation solutions, and other bioprocessing technologies aimed at supporting the growth of the regenerative medicine field.

How the Company Makes Money

ThermoGenesis Holdings generates revenue through the sale of its bioprocessing and cell therapy equipment, including automated cell separation systems and cryopreservation solutions. The company also earns income from licensing its proprietary technologies to other biotechnology firms and research institutions. Additionally, ThermoGenesis may engage in collaborations or partnerships where it provides its expertise and technology to support the development of new cell-based therapies, which can lead to milestone payments or royalties. The company's revenue is influenced by the growth of the regenerative medicine market and the adoption of automated solutions for cell processing.

ThermoGenesis Holdings Financial Statement Overview

Summary

ThermoGenesis Holdings is experiencing significant financial challenges with declining revenues, negative profit margins, and a concerning balance sheet marked by negative equity. Despite a slight improvement in free cash flow, liquidity and solvency issues persist.

Income Statement

ThermoGenesis Holdings has faced significant revenue decline with a negative revenue growth rate of -9.89% from 2022 to 2023. The net profit margin is negative, reflecting ongoing losses. Gross profit margin decreased to 20.44% in 2023, down from 25.85% in 2022, indicating increased cost pressures. EBIT and EBITDA margins are also negative, highlighting operational challenges. Overall, the income statement reveals declining revenues and persistent losses, suggesting financial difficulties.

Balance Sheet

The balance sheet shows a precarious financial position with negative stockholders' equity of -$1.67 million as of 2023, raising concerns about insolvency. The debt-to-equity ratio is not meaningful due to negative equity, indicating high leverage. The equity ratio is also negative, reflecting a weak capital structure. These factors suggest potential financial instability and risk to stakeholders.

Cash Flow

ThermoGenesis Holdings' cash flow statement indicates significant challenges, with negative free cash flow of -$5.45 million in 2023 compared to -$7.68 million in 2022, showing a slight improvement. The operating cash flow to net income ratio is not available, but persistently negative operating cash flows highlight liquidity issues. Overall, cash flow management remains a critical concern for the company.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	9.61M	9.45M	10.48M	9.29M	9.74M	13.05M
Gross Profit	2.03M	1.93M	2.71M	3.49M	1.26M	5.70M
EBITDA	-6.95M	-7.74M	-5.27M	-6.60M	-8.16M	-4.73M
Net Income	-14.74M	-17.98M	-11.27M	-11.38M	-16.35M	-9.50M
Balance Sheet
Total Assets	10.09M	11.23M	19.39M	20.65M	20.86M	15.21M
Cash, Cash Equivalents and Short-Term Investments	1.18M	2.00M	4.18M	7.28M	7.16M	3.16M
Total Debt	6.93M	10.56M	10.37M	10.46M	7.68M	5.69M
Total Liabilities	11.17M	14.82M	16.06M	17.25M	14.99M	14.30M
Stockholders Equity	975.00K	-1.67M	4.30M	3.83M	5.80M	386.00K
Cash Flow
Free Cash Flow	-4.59M	-5.45M	-7.68M	-6.71M	-14.42M	-3.44M
Operating Cash Flow	-3.61M	-3.72M	-7.28M	-6.62M	-14.39M	-3.26M
Investing Cash Flow	-982.00K	-1.73M	-400.00K	-93.00K	-23.00K	-182.00K
Financing Cash Flow	-82.00K	3.28M	4.59M	6.83M	17.42M	4.20M

ThermoGenesis Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VCEL	71 Outperform	$2.09B	1,043.80	1.13%	―	14.80%	530.21%
Sector *	64 Neutral	¥341.99B	10.89	-2.99%	2.57%	11.76%	-9.96%
AXGN	61 Neutral	$535.60M	―	-7.22%	―	18.81%	67.41%
CYRX	60 Neutral	$375.53M	―	-24.08%	―	-4.53%	5.24%
BLFS	57 Neutral	$1.07B	―	-3.29%	―	-23.12%	97.46%
STIM	43 Neutral	$231.40M	―	-152.14%	―	22.16%	-37.60%
THMO	39 Underperform	$16.00	―	1078.28%	―	-7.53%	77.39%